Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs Incyte Corporation — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $95.63, while Incyte Corporation trades at $116.43 (market cap $22.99B). The key difference: Incyte Corporation is trading nearer its 52-week high, iShares JPMorgan USD Emerging Markets Bond ETF nearer its low. Which is the better fit depends on your goals.
| EMB | INCY | |
|---|---|---|
Sector | Fixed Income | Health |
52-Week High | $97.74 | $118.52 |
52-Week Low | $91.59 | $67.38 |
Market Cap | — | $22.99B |
Enterprise Value | — | $19.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB trades at $95.54, down slightly by 0.03% on the day, with a bearish technical signal driven by moving averages. Recent corporate actions include scheduled dividends for 2026, with payouts of $0.41 and $0.40 per share. News highlights focus on emerging market bond risks and Federal Reserve policy impacts, with the ETF showing a 12% total return over the past year but only 1% year-to-date gains as of May 2026.
The outlook for EMB is cautious due to bearish technical indicators and macroeconomic sensitivities. Key risks include emerging market sovereign default exposure and interest rate volatility. Analyst sentiment is mixed, with attention on Fed policy and global bond market dynamics as critical drivers for future performance.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
